Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ginger Riddle

Physician Assistant Gainesville, FL Physician Assistant

NPI 1164704086 CMS profile 10901428

4645 Nw 8Th Ave, Gainesville, FL 32605

Open in the dashboard

General payments

$5,375

264 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ginger Riddle of Gainesville, FL is reported in the CMS Open Payments database as having received $5,375 across 264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $934 39
2024 General $1,148 64
2023 General $1,971 75
2022 General $839 57
2021 General $484 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ginger Riddle
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ginger Riddle were reported at $934. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ginger Riddle Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $484 $132 $37–$438 $132
2022 $839 $155 $48–$522 $149
2023 $1,971 $167 $52–$557 $160
2024 $1,148 $178 $55–$600 $164
2025 $934 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Biosense Webster, Inc. $778 40 payments
  2. Boston Scientific Corporation $545 4 payments
  3. Merck Sharp & Dohme Corporation $488 25 payments
  4. Novartis Pharmaceuticals Corporation $487 29 payments
  5. E.R. Squibb & Sons, L.L.C. $485 52 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $394 20 payments
  7. AstraZeneca Pharmaceuticals LP $278 15 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $263 10 payments
  9. CVRx, Inc. $216 7 payments
  10. Abbott Laboratories $142 6 payments
  11. Other $1,300 56 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,865 261 payments
  2. Travel and Lodging $496 2 payments
  3. Education $14 1 payment
Products named General payments · program years 2021–2025
  1. Carto 3 $798 41 payments
  2. VERQUVO $549 28 payments
  3. Varithena Administration Pack $496 2 payments
  4. JARDIANCE $299 15 payments
  5. CAMZYOS $276 26 payments
  6. LifeVest $263 10 payments
  7. FARXIGA $260 14 payments
  8. Barostim Neo System $216 7 payments
  9. ELIQUIS $193 23 payments
  10. LEQVIO $192 11 payments
  11. Other $2,483 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,900

Median for Physician Assistant: 241

Drug cost

$683,180

Median for Physician Assistant: $4,110

Branded share of claims

37.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 246 $291,599
Entresto Sacubitril/Valsartan Brand 94 $117,616
Xarelto Rivaroxaban Brand 104 $113,129
Multaq Dronedarone Hcl Brand 39 $44,839
Jardiance Empagliflozin Brand 41 $37,860
Verquvo Vericiguat Brand 19 $20,391
Ozempic Semaglutide Brand 19 $16,382
Farxiga Dapagliflozin Propanediol Brand 22 $11,982
Dofetilide Generic 12 $5,893
Flecainide Acetate Generic 61 $2,818

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $98
$98 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $68
$68 104 —
VERQUVO
  • Merck Sharp & Dohme Corporation $62
$62 19 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $58
$58 22 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $47
$47 246 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record